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Hospital Medical Center in Flushing, 
New York, with complaints of head-
ache, fever, and vomiting, which she 
had experienced for ≈1 week. She had 
no  photophobia,  confusion,  or  rash; 
neurologic examination found no ab-
normalities. CSF contained 81 leuko-
cytes with 82% lymphocytes, 3 eryth-
rocytes,  protein  at  194  mg/dL,  and 
glucose at 67 mg/dL. CSF was posi-
tive for HSV-1 viral DNA by PCR. A 
computed  tomography  (CT)  scan  of 
the head showed unilateral temporal 
lobe  edema.  Intravenous  acyclovir 
10 mg/kg every 8 hours was adminis-
tered. HIV test was negative. On day 
5, a repeat CT scan showed worsening 
edema and hemorrhage, despite clini-
cal improvement (Figure). CSF con-
tained 490 leukocytes with 99% lym-
phocytes  and  protein  at  336  mg/dL. 
After  continued  treatment  with  par-
enteral acyclovir, the patient’s symp-
toms resolved. On day 12, the patient 
was discharged after a final CT scan 
showed resolution of hemorrhage and 
edema and CSF contained decreased 
leukocytes and protein.
Although this patient had classic 
signs of meningitis without encepha-
litis, the CT scan of the head showed 
cerebral  involvement.  These  factors 
can  be  explained  by  the  location  of 
cerebral inflammation in the nondom-
inant lobe of the brain, thereby mask-
ing signs of encephalitis. The classic 
teaching that viral meningitis may not 
need  treatment  may  miss  the  occa-
sional viral encephalitis if brain imag-
ing and CSF PCR are not performed. 
Failure to perform these tests may lead 
to illness and death from HSV enceph-
alitits if this disease is not considered 
as a possible diagnosis.
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Tick-Borne  
Rickettsiosis in 
Traveler Returning 
from Honduras
To  the  Editor:  Although  tick-
borne  rickettsioses  are  widespread 
globally, few reports document their 
presence in Central America (1). Sero-
surveys detected rickettsial antibodies 
in humans in Central America in 1971 
in Costa Rica, Honduras, Nicaragua, 
and  Panama  (2,3).  An  outbreak  of 
rickettsial illness was reported to have 
occurred in Costa Rica in 1974, where 
2 case clusters affected 6 of 15 fam-
ily members (4). A rickettsial organ-
ism was isolated from a patient who 
died in Panama in 1950 (5), and more 
recently Rickettsia rickettsii was con-
Figure.	Computed	tomograph	scan	showing	hemorrhage	in	edematous	part	of	brain	of	
patient	with	herpes	simplex	virus	encephalitis,	day	5	of	hospitalization.LETTERS
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firmed in a fatal case in Panama (6). 
We report a patient with serologic evi-
dence of rickettsiosis after a tick bite 
sustained during travel in Honduras.
A 51-year-old man sought medical 
evaluation after returning from travel 
to  Roatan,  Honduras,  where  he  was 
bitten by a tick in the lower abdomen. 
He reported erythema and induration 
at the site of the tick bite with asso-
ciated central necrosis. He described 
an illness with headache, fever, weak-
ness,  dizziness,  abdominal  discom-
fort, diarrhea, flu-like symptoms, and 
respiratory  symptoms  affecting  him 
1–2 weeks after the tick bite. He was 
evaluated  while  still  traveling  and 
received  multiple  diagnoses,  includ-
ing malaria, respiratory infection, and 
parasites, and was given chloroquine, 
primaquine, penicillin, and mebenda-
zole. His condition improved. He re-
turned to the United States 2 months 
after the tick bite.
His travel history included Thai-
land,  Jamaica, Aruba,  the  Bahamas, 
Belize, Germany, Spain, Hungary, the 
Netherlands,  and  New  Zealand. The 
patient recalled removing ticks from 
his body as a child in Maryland but 
had no associated illness. He denied 
any recent tick bite other than the one 
in Honduras, where he had close con-
tact with a horse and dogs and was fre-
quently outdoors.
Results of his physical examina-
tion were unremarkable; routine labo-
ratory  studies  showed  values  within 
reference  ranges.  No  antibodies  to 
Borrelia  burgdorferi  or  Plasmodium 
spp. were detected.
Serologic analysis for rickettsia, 
performed  by  a  commercial  labora-
tory  (Focus  Diagnostics,  Cypress, 
CA, USA) and the Centers for Disease 
Control and Prevention (Atlanta, GA, 
USA), showed elevated titers (Table). 
The patient took doxycycline (100 mg 
2×/d)  for  10  days  and  subjectively   
improved.
On the basis of infections docu-
mented in the Americas, R. rickettsii, 
R. africae, and other less well-known 
rickettsial pathogens such as R. park-
eri  or  R.  massiliae ( 1)  are  possible 
etiologic agents in our case. The most 
common human-biting tick in Central 
America  is  Amblyomma  cajennense, 
which is a known vector of R. rick-
ettsii. Serosurveys have suggested the 
presence of R. rickettsii infection in the 
Yucatan (7), and PCR has confirmed a 
case of R. rickettsii in that region (8). 
Rhipicephalus  sanguineus,  the  vec-
tor of R. conorii (boutonneuse fever) 
in the Mediterranean, is also found in 
Mexico, but to date no transmission 
of R. conorii has been documented in 
the Americas. R. sanguineus was im-
plicated in a cluster of human Rocky 
Mountain  spotted  fever  cases  in  the 
United States in 2002–2004 (9).
Our patient had not traveled to 
the  areas  of  the  Caribbean  where 
transmission of R. africae has been 
documented, but he had lived in ar-
eas  of  the  United  States  with  po-
tential  transmission  of  rickettsial 
infections. R. parkeri is a newly rec-
ognized  pathogen  in  the  Americas 
(10). Its vectors (A. maculatum and 
A. triste) are found in parts of North, 
Central, and South America. The ill-
ness caused by R. parkeri appears to 
be less severe than Rocky Mountain 
spotted fever and could be consistent 
with  our  patient’s  illness.  Because 
antibodies against R. parkeri and R. 
rickettsii cross-react, serologic analy-
sis is of little use for differentiating 
these 2 organisms.
The  history  and  serologic  find-
ings for our patient suggest a recent 
tick-borne  rickettsiosis,  most  likely 
acquired in Honduras. However, we 
can neither confirm that infection was 
recent nor confirm the species. The 
history of a tick bite and description 
of the skin lesion are consistent with 
an eschar, but no physical evidence of 
the tick or eschar remained at the time 
of evaluation. Diagnosis of rickettsial 
infection can be confirmed by dem-
onstrating at least a 4-fold increase 
in  titers  between  acute-phase  and 
convalescent-phase  serum  samples, 
by identification of rickettsiae in an 
acute-phase serum or tissue sample, 
or by culture. Use of an immunofluo-
rescent antibody assay alone does not 
identify  the  specific  agent  causing 
spotted fever.
Because our patient was examined 
2 months after the exposure, options 
for making a diagnosis were limited. 
Extensive  serologic  cross-reactivity 
exists  among  the  rickettsial  species, 
which precludes the determination of 
species in our case. Although antibod-
ies  to  rickettsiae  can  be  long-lived, 
the extremely high levels of immuno-
globulin (Ig) G and IgM suggest a re-
cent rickettsial infection in our patient. 
Testing was unavailable for other rick-
ettsiae (e.g., R. parkeri, R. massiliae).
Table. Rickettsia	spp.	serologic	titers	for	a	man	who	returned	from	Honduras,	2005*	
Titers	on	specific	date	
Test  May	26 Jun	10	 Jul	14 Aug	25 Nov	22
RMSF	IgG† Positive,
>1,024
Positive,
>1,024
Positive,
>1,024
Positive,
>1,024
RMSF	IgM† Positive,
512
Positive,
256
Positive,
128
Positive,
256
R. conorii	IgG† >1,024 512 512
R. conorii	IgM† 64 64 64
R. africae IgG‡ 2,048 4,096
R. africae	IgM‡ 512
R. conorii IgG‡ 2,048 4,096
R. conorii	IgM‡ 512
R. rickettsii IgG‡ 1,024
R. rickettsii	IgM‡ 256
*Reference	titer	for	negative/normal	result	is	<64.	RMSF,	Rocky	Mountain	spotted	fever;	Ig,	
immunoglobulin.
†Testing	done	by	Focus	Diagnostics,	Cypress,	CA,	USA.	
‡Testing	done	by	Centers	for	Disease	Control	and	Prevention,	Atlanta,	GA,	USA.		LETTERS
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Our patient likely had rickettsial 
infection  acquired  in  Honduras.  We 
present this case to alert clinicians to 
consider the diagnosis of rickettsial in-
fections in the Americas, even if infec-
tions have not been previously docu-
mented in a specific country or region. 
Because rickettsial infections can be 
severe and are treatable, the clinician 
should consider rickettsial infections 
in returned travelers with compatible 
clinical findings. Our case also dem-
onstrates the potential role of travel-
ers as sentinels of emerging infectious 
diseases.
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KI and WU  
Polyomaviruses in 
Patients Infected 
with HIV-1, Italy
To the Editor: Before 2007, two 
human polyomaviruses were known to 
infect humans: BK virus and JC virus 
(1,2).  Recently,  2  novel  polyomavi-
ruses, KI polyomavirus (KIPyV) and 
WU  polyomavirus  (WUPyV),  were 
identified in the respiratory secretions 
of children with signs of acute respira-
tory signs (3,4); little evidence exists 
to suggest that these viruses are caus-
ative agents of respiratory tract disease 
(5).  To  determine  the  prevalence  of 
WUPyV and KIPyV in the plasma of 
HIV-1–infected patients, we screened 
62 persons who were HIV-1 positive 
by using PCR to detect the 2 viruses. 
We also conducted phylogenetic anal-
ysis of the identified strains.
Plasma specimens were collected 
at Istituto di Ricovero e Cura a Carat-
tere Scientifico Instituto Fisioterapico 
Ospetaliere–San  Gallicano  Institute 
and Tor Vergata University Hospital, 
Rome, Italy, from April 2005 through 
September 2008. Patients were adults 
(37–54 years of age, median age 45.5 
years)  and  were  being  treated  with 
antiretroviral drugs. HIV-1 viral load 
determination,  CD4+  counts,  and 
HIV-1 genotyping were performed as 
part of the routine investigation. Plas-
ma  viremia  levels  ranged  from  <50 
to  2,877,764  copies/mL,  and  CD4+ 
counts  ranged  from  150  to  1,218. 
Most patients (64.5%) were infected 
by HIV-1 subtype B. Other subtypes 
found were F, G, and C.
Total DNA was extracted from 0.2 
mL of plasma by using the QIAamp 
DNA Mini Kit according to the man-
ufacturer’s  instruction  (QIAGEN   
S.p.A., Milan, Italy) and then stored 
at  –80ºC  until  analysis.  KIPyV  and 
WUPyV  PCR  screening  was  carried 
out  as  described  (3,4).  Positive  iso-
lates  were  reamplified  with  primers 
encompassing the N-terminal part of 
the large T antigen (T-Ag) and almost 
the entire small t antigen (t-Ag) genes. 
KIPyV was amplified as described (6), 
and,  for  WUPyV,  the  primers  were 
FWUV4460  5 ′-ACTGAGACCAC-
CAGTAATCCCAG-3 ′  (4460–4482 
nt) and RWUV5200 5 ′-AAGCAGAG-
GGCCTTGCTGAGGCG-3 ′  (5200–
5178 nt). The thermal cycling profile 
was 1 cycle at 94ºC for 10 min and 
then 40 cycles at 94ºC for 30 s, at 65ºC 
for 30 s, and at 72ºC for 60 s. The am-
plified t-Ag fragments were sequenced 
as  described  (6).  The  obtained  se-
quences (KIV-RM21, KIV-RM22, and 
WU-IT3) were submitted to GenBank 
(accession nos. FJ842112–FJ842114) 
and  matched  against  all  deposited 
sequences  (www.ncbi.nlm.nih.gov/
BLAST).  ClustalX  software  (http://
bips.u-strasbg.fr/fr/documentation/